Repligen (RGEN) Tops Q3 EPS by 7c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus

October 31, 2019 7:39 AM

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.26, $0.07 better than the analyst estimate of $0.19. Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found